
US-based CritiTech, Inc. specializes in R&D of fine-particle compounds for API production and coatings.
Founded in Lawrence, United States, CritiTech, Inc. is dedicated to the research and development of fine-particle compounds, primarily for Active Pharmaceutical Ingredient (API) production and coatings. The company's core mission is to enhance drug development processes and improve patient outcomes through innovative particle technology. CritiTech serves pharmaceutical companies across the United States, offering specialized Contract Development and Manufacturing Organization (CDMO) services to help clients bring their drugs to market efficiently.
CritiTech has garnered attention for its cutting-edge approach to drug development, attracting partnerships with notable pharmaceutical firms. The company's achievements include successful collaborations that have led to improved drug formulations and delivery systems. By focusing on fine-particle technology, CritiTech has made a significant impact on the pharmaceutical industry, contributing to the advancement of more effective and accessible medications.
Critical Biologics

Apertus Pharmaceuticals

Bright Path Laboratories
brightpathlabs.com

Ambiopharm
ambiopharm.com

Societal Cdmo
societalcdmo.com

Cristcot
cristcot.com

BiotechInnova
biotechinnova.com

Astatech
astatechinc.com

Pinpoint Pharma
pinpointpharma.co

AmericanPharma Technologies

Scienture
scienture.com

Crinetics Pharmaceuticals
crinetics.com

Phlow
phlow-usa.com

Parimer Scientific
parimer.com

Proteotech
Companies similar to Crititech include Critical Biologics, Apertus Pharmaceuticals, Bright Path Laboratories and Ambiopharm.
Crititech was founded in 1997.
Crititech's headquarters is located in Lawrence, KS, US.
Crititech's most recent funding round was for $7.5M (USD) in April 2019.
As of Apr 1, 2019, Crititech has raised a total of $13.2M (USD).
Crititech has 33 employees as of Feb 5, 2024.